Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?

J Am Coll Cardiol. 2012 Jul 31;60(5):378-80. doi: 10.1016/j.jacc.2012.03.033. Epub 2012 Jun 6.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Abciximab
  • Angioplasty, Balloon, Coronary*
  • Antibodies, Monoclonal / therapeutic use*
  • Anticoagulants / therapeutic use*
  • Antithrombins / therapeutic use*
  • Clopidogrel
  • Female
  • Heparin / therapeutic use*
  • Hirudins
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Male
  • Myocardial Infarction / therapy*
  • Peptide Fragments / therapeutic use*
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Stents*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Antithrombins
  • Hirudins
  • Immunoglobulin Fab Fragments
  • Peptide Fragments
  • Platelet Aggregation Inhibitors
  • Recombinant Proteins
  • Heparin
  • Clopidogrel
  • Ticlopidine
  • bivalirudin
  • Abciximab